01996nam a2200397 i 4500001001300000003000300013005001700016007001400033008004100047040003000088042000800118043001200126050002000138074001600158086002300174088010200197110009400299245020500393264006000598300002700658336002600685337002700711338003100738500003600769500010800805500002600913500002500939504004100964533010701005610003501112650003901147650005001186655003301236776017301269776015601442on1008755216BD20171226144813.0he bmb024bbca171031s2017    dcu     bb   f000 0 eng c  aPUCPRbengerdacGPOdMvI  apcc  an-us---14aKF27b.O94 2016  a1016-B (MF)0 aY 4.G 74/7:114-124  aSerial no. 114-124 (United States. Congress. House. Committee on Oversight and Government Reform)1 aUnited States.bCongress.bHouse.bCommittee on Oversight and Government Reform,eauthor.10aReviewing the rising price of EpiPens :bhearing before the Committee on Oversight and Government Reform, House of Representatives, One Hundred Fourteenth Congress, second session, September 21, 2016. 1aWashington :bU.S. Government Publishing Office,c2017.  aiii, 95 pages ;c24 cm  atextbtxt2rdacontent  amicroformbh2rdamedia  amicrofichebhe2rdacarrier  aShipping list no.: 2017-0115-M.  aPaper version available for sale by the Superintendent of Documents, U.S. Government Publishing Office.  a"Serial no. 114-124."  aCRDP Program record.  aIncludes bibliographical references.  aMicrofiche.b[Washington, D.C.] :cU.S. Government Printing Office,d[2017]e2 microfiches : negative.20aMylan, IncxCorrupt practices. 0aAdrenalinexPriceszUnited States. 0aDrug delivery devicesxPriceszUnited States. 7aLegislative hearings.2lcgft08iPrint version:aUnited States. Congress. House. Committee on Oversight and Government Reform.tReviewing the rising price of EpiPensw(DLC) 2017392634w(OCoLC)98540923008iOnline version:aUnited States. Congress. House. Committee on Oversight and Government Reform.tReviewing the rising price of EpiPensw(OCoLC)984515142